Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Aggarwal

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Journal of Virology|October 19, 2023
Functional and transcriptional heterogeneity within the massively expanding HLADR<sup>+</sup>CD38<sup>+</sup> CD8 T cell population in acute febrile dengue patientsPrabhat Singh, Prashant Bajpai, Deepti Maheshwari, et al.
Cancer|October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs dataJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
JCO Oncology Practice|May 27, 2020
Management of Lung Cancer During the COVID-19 PandemicAditi P Singh, Abigail T Berman, Melina E Marmarelis, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
Scientific Reports|May 12, 2021
Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitorsBardia Yousefi, Michael J LaRiviere, Eric A Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.
The British Journal of Radiology|October 11, 2019
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancerJared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, et al.
The Oncologist|May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung CancerCharu Aggarwal, Alisha P Maity, Joshua M Bauml, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinibAdam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
International Journal of Particle Therapy|November 28, 2019
Quality of Life of Postoperative Photon versus Proton Radiation Therapy for Oropharynx CancerSonam Sharma, Olivia Zhou, Reid Thompson, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Journal of Virology|October 19, 2023
Functional and transcriptional heterogeneity within the massively expanding HLADR<sup>+</sup>CD38<sup>+</sup> CD8 T cell population in acute febrile dengue patientsPrabhat Singh, Prashant Bajpai, Deepti Maheshwari, et al.
Cancer|October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs dataJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
JCO Oncology Practice|May 27, 2020
Management of Lung Cancer During the COVID-19 PandemicAditi P Singh, Abigail T Berman, Melina E Marmarelis, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
Scientific Reports|May 12, 2021
Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitorsBardia Yousefi, Michael J LaRiviere, Eric A Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.
The British Journal of Radiology|October 11, 2019
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancerJared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, et al.
The Oncologist|May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung CancerCharu Aggarwal, Alisha P Maity, Joshua M Bauml, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinibAdam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
International Journal of Particle Therapy|November 28, 2019
Quality of Life of Postoperative Photon versus Proton Radiation Therapy for Oropharynx CancerSonam Sharma, Olivia Zhou, Reid Thompson, et al.
Pageof 17